Literature DB >> 29150274

Neuroprotective potential of high-dose biotin.

Mark F McCarty1, James J DiNicolantonio2.   

Abstract

A recent controlled trial has established that high-dose biotin supplementation - 100 mg, three times daily - has a stabilizing effect on progression of multiple sclerosis (MS). Although this effect has been attributed to an optimization of biotin's essential cofactor role in the brain, a case can be made that direct stimulation of soluble guanylate cyclase (sGC) by pharmacological concentrations of biotin plays a key role in this regard. The utility of high-dose biotin in MS might reflect an anti-inflammatory effect of cGMP on the cerebral microvasculature, as well on oligodendrocyte differentiation and on Schwann cell production of neurotrophic factors thought to have potential for managing MS. But biotin's ability to boost cGMP synthesis in the brain may have broader neuroprotective potential. In many types of neurons and neural cells, cGMP exerts neurotrophic-mimetic effects - entailing activation of the PI3K-Akt and Ras-ERK pathways - that promote neuron survival and plasticity. Hippocampal long term potentiation requires nitric oxide synthesis, which in turn promotes an activating phosphorylation of CREB via a pathway involving cGMP and protein kinase G (PKG). In Alzheimer's disease (AD), amyloid beta suppresses this mechanism by inhibiting sGC activity; agents which exert a countervailing effect by boosting cGMP levels tend to restore effective long-term potentiation in rodent models of AD. Moreover, NO/cGMP suppresses amyloid beta production within the brain by inhibiting expression of amyloid precursor protein and BACE1. In conjunction with cGMP's ability to oppose neuron apoptosis, these effects suggest that high-dose biotin might have potential for the prevention and management of AD. cGMP also promotes neurogenesis, and may lessen stroke risk by impeding atherogenesis and hypertrophic remodeling in the cerebral vasculature. The neuroprotective potential of high-dose biotin likely could be boosted by concurrent administration of brain-permeable phosphodiesterase-5 inhibitors.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimers disease; Beta-amyloid; Biotin; Cgmp; Multiple sclerosis; Neurotrophic factors; Phosphodiesterase-5; Protein kinase G; Schwann cells; Soluble guanylate cyclase

Mesh:

Substances:

Year:  2017        PMID: 29150274     DOI: 10.1016/j.mehy.2017.10.012

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

1.  Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.

Authors:  Laura Bianchi; Maria Sframeli; Lorenza Vantaggiato; Gian Luca Vita; Annamaria Ciranni; Francesca Polito; Rosaria Oteri; Eloisa Gitto; Fabrizio Di Giuseppe; Stefania Angelucci; Antonio Versaci; Sonia Messina; Giuseppe Vita; Luca Bini; M'hammed Aguennouz
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

2.  Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin.

Authors:  Alexis Demas; Jean-Philippe Cochin; Clémence Hardy; Yvan Vaschalde; Bertrand Bourre; Pierre Labauge
Journal:  Neurol Ther       Date:  2019-12-19

Review 3.  A Fundamental Role for Oxidants and Intracellular Calcium Signals in Alzheimer's Pathogenesis-And How a Comprehensive Antioxidant Strategy May Aid Prevention of This Disorder.

Authors:  Mark F McCarty; James J DiNicolantonio; Aaron Lerner
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

Review 4.  Revised D-A-CH reference values for the intake of biotin.

Authors:  Alexandra Jungert; Sabine Ellinger; Bernhard Watzl; Margrit Richter
Journal:  Eur J Nutr       Date:  2022-01-03       Impact factor: 4.865

5.  Chronic-Antibiotics Induced Gut Microbiota Dysbiosis Rescues Memory Impairment and Reduces β-Amyloid Aggregation in a Preclinical Alzheimer's Disease Model.

Authors:  Paola C Bello-Medina; Karina Corona-Cervantes; Norma Gabriela Zavala Torres; Antonio González; Marcel Pérez-Morales; Diego A González-Franco; Astrid Gómez; Jaime García-Mena; Sofía Díaz-Cintra; Gustavo Pacheco-López
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 6.  B Vitamins and Fatty Acids: What Do They Share with Small Vessel Disease-Related Dementia?

Authors:  Rita Moretti; Costanza Peinkhofer
Journal:  Int J Mol Sci       Date:  2019-11-18       Impact factor: 5.923

Review 7.  Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.

Authors:  Mark F McCarty
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.